


Bioactive

CTGF (Human) Recombinant Protein

Catalog # P4578

Size 20 ug

Applications



Lane 1: non-reducing conditions

Lane 2: reducing conditions

Result of activity analysis

Result of activity analysis

Serial dilutions of human CTGF, starting at 10 ug/mL, were added to HUVECs cultured without EGF. Cell proliferation was measured after 87 hours and the linear portion of the curve was used to calculate the ED50.

Specification

Product Description	Human CTGF (P29279) recombinant protein expressed in <i>Escherichia coli</i> .
Sequence	MGKKCI RTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCTPHRTTTL PVEFKCPDGEVMKKN MMFIKTCACHYNC PGDNDIFESLYRKMYGDMA
Host	Escherichia coli
Theoretical MW (kDa)	11.2
Form	Lyophilized
Preparation Method	<i>Escherichia coli</i> expression system
Endotoxin Level	< 0.1 EU/ug

Activity	The activity is determined by the dose-dependent induction of HUVEC proliferation. The expected E _{D50} for this effect is 1.1-1.7 ug/mL.
Quality Control Testing	1 ug/lane in 4-20% Tris-Glycine gel Stained with Coomassie Blue Lane 1: non-reducing conditions Lane 2: reducing conditions
Storage Buffer	Lyophilized with 10 mM sodium acetate, pH 6.0.
Storage Instruction	Store at -20°C on dry atmosphere. After reconstitution with 5 mM sodium acetate, store at -20°C. Aliquot to avoid repeated freezing and thawing.
Note	Result of activity analysis Result of activity analysis Serial dilutions of human CTGF, starting at 10 ug/mL, were added to HUVECs cultured without EGF. Cell proliferation was measured after 87 hours and the linear portion of the curve was used to calculate the ED50.

Applications

- Functional Study
- SDS-PAGE

Gene Info — CTGF

Entrez GeneID	1490
Protein Accession#	P29279
Gene Name	CTGF
Gene Alias	CCN2, HCS24, IGFBP8, MGC102839, NOV2
Gene Description	connective tissue growth factor
Omim ID	121009
Gene Ontology	Hyperlink
Other Designations	OTTHUMP00000017213 hypertrophic chondrocyte-specific protein 24 insulin-like growth factor-binding protein 8

Publication Reference

- [Nell-1, HMGB1 and CCN2 enhance migration and vasculogenesis, but not osteogenic differentiation compared to BMP2.](#)

Fahmy-Garcia S, van Driel M, Witte-Buoma J, Walles H, van Leeuwen JP, van Osch G, Farrell E.

Tissue Engineering Part A. 2017 May; [Epub].

Application: Func, Human, HUVEC, MSC cells

Disease

- [Adenocarcinoma](#)
- [Aortic Valve Stenosis](#)
- [Biliary Atresia](#)
- [Calcinosis](#)
- [Death](#)
- [Diabetes Mellitus](#)
- [Diabetic Nephropathies](#)
- [Disease Susceptibility](#)
- [Esophageal Neoplasms](#)
- [Fibrosis](#)
- [Genetic Predisposition to Disease](#)
- [Hypoglycemia](#)
- [Inflammation](#)
- [Liver Cirrhosis](#)
- [Lung Diseases](#)
- [Lung Neoplasms](#)
- [Ovarian Neoplasms](#)

- [Pulmonary Disease](#)
- [Schistosomiasis](#)
- [Scleroderma](#)